头孢地秦对肺癌患者细胞免疫系统的影响

Effect of cefodizime on cellular immunity in patients with lung cancer

目的 探讨头孢地秦对肺癌患者细胞免疫的增强作用。方法 选择肺癌并发呼吸系统感染患者４５ 例，同期选择呼吸系统感染患者１０ 例。检测各组外周血和肺泡局部细胞免疫指标。结果 （１）用头孢地秦的肺癌患者外周血中性粒细胞的硝基四唑氮蓝（ＮＢＴ） 阳性率、ＮＫ 细胞计数、ＣＤ＋４细胞计数、ＣＤ＋４ ／ＣＤ＋８ 比值、肺泡巨噬细胞（ＡＭ） 吞噬中性红的吸光度（ Ａ，旧称光密度ＯＤ） 以及支气管肺泡灌洗液中ＩＬ１β浓度均显著高于未用药者，并可达到非肺癌呼吸系统感染患者水平。（２） 用头孢地秦的肺癌患者外周血中性粒细胞的ＮＢＴ阳性率、ＣＤ＋３ 细胞计数、ＣＤ＋４ 细胞计数、ＣＤ＋４ ／ＣＤ＋８ 比值以及ＡＭ 吞噬中性红的吸光度均显著高于用头孢三嗪的肺癌患者。结论 头孢地秦可明显增强肺癌患者外周血和肺泡局部的免疫功能。

Objective To study the enhancing effect of cefodizime on cellular immunity of patients with lung cancer.Methods The parameters of cellular immunity in blood and pulmonary alveoli were investigated in 45 patients with lung cancer complicated with lower respiratory tract infection (LRTI) and 10 non cancer patients with LRTI. Nitroblue tetrazolium (NBT) reaction of polymorphonuclear neutrophils (PMN), the perecntage of natural killer (NK) cells, and that of CD + 4 cells, ratio of CD + 4/CD + 8 in peripheral blood, OD value of alveolar macrophages phagocyting neutral red, and IL 1β (ng/L) in broncho alveolar lavage flind (BALF) were determined.Results The parameters examined in cancer patients with LRTI were significantly improved after cefodizime treatment, approaching to those seen in non cancer patients with LRTI. The therapeutic results were better in patients treated with cifodizime than in patients treated with ceftriaxonum.Conclusion Cefodizime is a better choice of antibiotic for the treatment of lung cancer complicated with lower respiratory tract infection. Its enhancing effect on systemic and local immune functions plays a role.